CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a clinical-stage neurotechnology company pioneering neuromodulation-based treatments for neurodegenerative diseases, announced five new poster ...
- Continued active treatment in the OVERTURE II OLE study demonstrated durability and preservation of brain structure and volume via MRI measurements over 18 months - Spectris™ treatment was well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results